共 242 条
[1]
McGuire S(2016)World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015 Adv Nutr 7 418-419
[2]
Mottet N(2017)EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent Eur Urol 71 618-629
[3]
Bellmunt J(2015)68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42 1284-1294
[4]
Bolla M(2017)EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer Eur Urol 71 630-642
[5]
Briers E(2010)Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy Eur J Nucl Med Mol Imaging 37 301-309
[6]
Cumberbatch MG(2009)[(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy World J Urol 27 619-625
[7]
De Santis M(2014)Is choline PET/CT already clinically useful in patients with prostate cancer? J Nucl Med 55 1401-1403
[8]
Ceci F(2016)New clinical indications for 18F/11C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature Eur Urol 70 161-175
[9]
Uprimny C(2013)The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis Eur Urol 64 106-117
[10]
Nilica B(1994)Expression of the prostate-specific membrane antigen Cancer Res 54 1807-1811